Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer

it was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC). In this study, 70 patients with stage IV...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuan Zhou, Ting Jin, Likun Wang, Erlin Zhao, Xuyang Xiao
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki) hyaluronic acid-gadolinium sesquioxide-nanoparticles (ha-gd2o3-nps) non-small cell lung cancer (nsclc) clinic Biotechnology TP248.13-248.65
Acceso en línea:	https://doaj.org/article/25ea2d937cd940eab6a7769368822c27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:25ea2d937cd940eab6a7769368822c27
record_format	dspace
spelling	oai:doaj.org-article:25ea2d937cd940eab6a7769368822c272021-11-26T11:19:50ZClinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer2165-59792165-598710.1080/21655979.2021.2009969https://doaj.org/article/25ea2d937cd940eab6a7769368822c272021-11-01T00:00:00Zhttp://dx.doi.org/10.1080/21655979.2021.2009969https://doaj.org/toc/2165-5979https://doaj.org/toc/2165-5987it was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC). In this study, 70 patients with stage IV EGFR mutant NSCLC diagnosed in the First Affiliated Hospital of Jinzhou Medical Universitywere selected. They were randomly divided into the combined group (35 cases) and the control group (35 cases). HA-Gd2O3-NPs were prepared by hydrothermal polymerization, and combined with EGFR-TKI in the clinical treatment of NSCLC. The results showed that HA-Gd2O3-NPs were spherical with uniform particle size of about 124 nm. The NSCLC survival rate of the combined group was 37.2 ± 5.3 % under 6Gy X-ray irradiation, and that of the control group was 98.4 ± 12.6 % under 6Gy X-ray irradiation. The total effective rate of the control group (20 %) was significantly lower than that of the study group (42.86 %) (P < 0.05). The one-year survival rate of the combined group (94 %) was significantly higher than that of the control group (75 %) (P < 0.05). The median progression-free survival (PFS) in the control group was 8 months, and that in the combined group was 12 months, with statistical difference (P < 0.05). EGFR-TKI targeted drugs combined with HA-Gd2O3-NPs can significantly improve the clinical efficacy of stage IV EGFR mutant NSCLC patients and benefit their survival.Xuan ZhouTing JinLikun WangErlin ZhaoXuyang XiaoTaylor & Francis Grouparticleepidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki)hyaluronic acid-gadolinium sesquioxide-nanoparticles (ha-gd2o3-nps)non-small cell lung cancer (nsclc)clinicBiotechnologyTP248.13-248.65ENBioengineered, Vol 0, Iss 0 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki) hyaluronic acid-gadolinium sesquioxide-nanoparticles (ha-gd2o3-nps) non-small cell lung cancer (nsclc) clinic Biotechnology TP248.13-248.65
spellingShingle	epidermal growth factor receptor-tyrosine kinase inhibitor (egfr-tki) hyaluronic acid-gadolinium sesquioxide-nanoparticles (ha-gd2o3-nps) non-small cell lung cancer (nsclc) clinic Biotechnology TP248.13-248.65 Xuan Zhou Ting Jin Likun Wang Erlin Zhao Xuyang Xiao Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
description	it was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC). In this study, 70 patients with stage IV EGFR mutant NSCLC diagnosed in the First Affiliated Hospital of Jinzhou Medical Universitywere selected. They were randomly divided into the combined group (35 cases) and the control group (35 cases). HA-Gd2O3-NPs were prepared by hydrothermal polymerization, and combined with EGFR-TKI in the clinical treatment of NSCLC. The results showed that HA-Gd2O3-NPs were spherical with uniform particle size of about 124 nm. The NSCLC survival rate of the combined group was 37.2 ± 5.3 % under 6Gy X-ray irradiation, and that of the control group was 98.4 ± 12.6 % under 6Gy X-ray irradiation. The total effective rate of the control group (20 %) was significantly lower than that of the study group (42.86 %) (P < 0.05). The one-year survival rate of the combined group (94 %) was significantly higher than that of the control group (75 %) (P < 0.05). The median progression-free survival (PFS) in the control group was 8 months, and that in the combined group was 12 months, with statistical difference (P < 0.05). EGFR-TKI targeted drugs combined with HA-Gd2O3-NPs can significantly improve the clinical efficacy of stage IV EGFR mutant NSCLC patients and benefit their survival.
format	article
author	Xuan Zhou Ting Jin Likun Wang Erlin Zhao Xuyang Xiao
author_facet	Xuan Zhou Ting Jin Likun Wang Erlin Zhao Xuyang Xiao
author_sort	Xuan Zhou
title	Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
title_short	Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
title_full	Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
title_fullStr	Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
title_full_unstemmed	Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
title_sort	clinical practice of epidermal growth factor receptor-tyrosine kinase inhibitor targeted drugs combined with gadolinium oxide nanoparticles in the treatment of non-small cell lung cancer
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/25ea2d937cd940eab6a7769368822c27
work_keys_str_mv	AT xuanzhou clinicalpracticeofepidermalgrowthfactorreceptortyrosinekinaseinhibitortargeteddrugscombinedwithgadoliniumoxidenanoparticlesinthetreatmentofnonsmallcelllungcancer AT tingjin clinicalpracticeofepidermalgrowthfactorreceptortyrosinekinaseinhibitortargeteddrugscombinedwithgadoliniumoxidenanoparticlesinthetreatmentofnonsmallcelllungcancer AT likunwang clinicalpracticeofepidermalgrowthfactorreceptortyrosinekinaseinhibitortargeteddrugscombinedwithgadoliniumoxidenanoparticlesinthetreatmentofnonsmallcelllungcancer AT erlinzhao clinicalpracticeofepidermalgrowthfactorreceptortyrosinekinaseinhibitortargeteddrugscombinedwithgadoliniumoxidenanoparticlesinthetreatmentofnonsmallcelllungcancer AT xuyangxiao clinicalpracticeofepidermalgrowthfactorreceptortyrosinekinaseinhibitortargeteddrugscombinedwithgadoliniumoxidenanoparticlesinthetreatmentofnonsmallcelllungcancer
_version_	1718409455560818688

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer

Ejemplares similares